| Once-weekly semaglutide in adults with overweight or obesity JPH Wilding, RL Batterham, S Calanna, M Davies, LF Van Gaal, I Lingvay, ... New England Journal of Medicine 384 (11), 989-1002, 2021 | 2684 | 2021 |
| Tirzepatide once weekly for the treatment of obesity AM Jastreboff, LJ Aronne, NN Ahmad, S Wharton, L Connery, B Alves, ... New England Journal of Medicine 387 (3), 205-216, 2022 | 1712 | 2022 |
| Obesity in adults: a clinical practice guideline S Wharton, DCW Lau, M Vallis, AM Sharma, L Biertho, ... Cmaj 192 (31), E875-E891, 2020 | 1266 | 2020 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled … PM O'Neil, AL Birkenfeld, B McGowan, O Mosenzon, SD Pedersen, ... The Lancet 392 (10148), 637-649, 2018 | 699 | 2018 |
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension JPH Wilding, RL Batterham, M Davies, LF Van Gaal, K Kandler, K Konakli, ... Diabetes, Obesity and Metabolism 24 (8), 1553-1564, 2022 | 431 | 2022 |
| Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial WT Garvey, RL Batterham, M Bhatta, S Buscemi, LN Christensen, JP Frias, ... Nature medicine 28 (10), 2083-2091, 2022 | 396 | 2022 |
| Barriers to obesity treatment M Mauro, V Taylor, S Wharton, AM Sharma European journal of internal medicine 19 (3), 173-180, 2008 | 346 | 2008 |
| Substantial changes in epicardial fat thickness after weight loss in severely obese subjects G Iacobellis, N Singh, S Wharton, AM Sharma Obesity 16 (7), 1693-1697, 2008 | 304 | 2008 |
| Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 RF Kushner, S Calanna, M Davies, D Dicker, WT Garvey, B Goldman, ... Obesity 28 (6), 1050-1061, 2020 | 265 | 2020 |
| Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial LJ Aronne, N Sattar, DB Horn, HE Bays, S Wharton, WY Lin, NN Ahmad, ... Jama 331 (1), 38-48, 2024 | 217 | 2024 |
| Daily oral GLP-1 receptor agonist orforglipron for adults with obesity S Wharton, T Blevins, L Connery, J Rosenstock, S Raha, R Liu, X Ma, ... New England Journal of Medicine 389 (10), 877-888, 2023 | 193 | 2023 |
| Moderate alcohol consumption during pregnancy and the incidence of fetal malformations: a meta-analysis D Polygenis, S Wharton, C Malmberg, N Sherman, D Kennedy, G Koren, ... Neurotoxicology and teratology 20 (1), 61-67, 1998 | 137 | 1998 |
| Medications that cause weight gain and alternatives in Canada: a narrative review S Wharton, L Raiber, KJ Serodio, J Lee, RAG Christensen Diabetes, metabolic syndrome and obesity: targets and therapy, 427-438, 2018 | 122 | 2018 |
| Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery S Wharton, JL Kuk, M Luszczynski, E Kamran, RAG Christensen Clinical obesity 9 (4), e12323, 2019 | 119 | 2019 |
| Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice S Wharton, M Davies, D Dicker, I Lingvay, O Mosenzon, DM Rubino, ... Postgraduate medicine 134 (1), 14-19, 2022 | 115 | 2022 |
| Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial EA Bohula, BM Scirica, SE Inzucchi, DK McGuire, AC Keech, SR Smith, ... The Lancet 392 (10161), 2269-2279, 2018 | 96 | 2018 |
| Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss S Wharton, S Calanna, M Davies, D Dicker, B Goldman, I Lingvay, ... Diabetes, Obesity and Metabolism 24 (1), 94-105, 2022 | 92 | 2022 |
| Interest, views and perceived barriers to bariatric surgery in patients with morbid obesity S Wharton, KJ Serodio, JL Kuk, N Sivapalan, A Craik, MA Aarts Clinical obesity 6 (2), 154-160, 2016 | 83 | 2016 |
| Edmonton Obesity Staging System prevalence and association with weight loss in a publicly funded referral‐based obesity clinic KL Canning, RE Brown, S Wharton, AM Sharma, JL Kuk Journal of Obesity 2015 (1), 619734, 2015 | 83 | 2015 |
| Real‐world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada S Wharton, A Liu, A Pakseresht, E Nørtoft, CL Haase, J Mancini, ... Obesity 27 (6), 917-924, 2019 | 82 | 2019 |
